Boardroom Alpha
10-K primary document
PODD · Annual Report (Form 10-K) · Filed February 18, 2026

Insulet Corp10-K exhibit

podd-exx1073_20251231x10k.htm
Document
Exhibit 10.73

MASTER EQUIPMENT AND SERVICES AGREEMENT
AMENDMENT #3

THIS AMENDMENT AND RESTATEMENT AGREEMENT #3 TO THE MASTER EQUIPMENT AND SERVICES AGREEMENT originally dated August 31, 2016 between Insulet Corporation and ATS Automation Tooling Systems Inc. as amended by the Amendment and Restatement Agreement dated August 31, 2021 and that Amendment and Restatement Agreement #2 dated August 31, 2022 (together, the “MESA”), is made and entered into as of 31 August 2024 (“Amendment Effective Date”) by and between:

1.Insulet Corporation, with offices at 100 Nagog Park, Acton, MA 01720 (“Insulet”); and

2.ATS Corporation (formerly ATS Automation Tooling Systems Inc.), a company registered under the laws of Ontario, Canada with its registered office situated at 730 Fountain St N, Cambridge, ON N3H 4R7, Canada (“ATS”).

(the “Parties”).

WHEREAS:

a)the Parties have previously entered into and executed the MESA (as amended);

b)the MESA is due to expire on August 31, 2024 and the Parties wish to extend the term of the MESA; and

c)the Parties therefore now wish to further amend the MESA as set out below with effect from the Amendment Effective Date.

NOW, THEREFORE, in consideration of the premises, the mutual covenants contained herein and other valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:

1.With effect from the Amendment Effective Date, the first sentence of Clause 2 shall be deleted in its entirety and shall be replaced by the following revised first sentence of Clause 2:

“2. This Agreement shall become effective on the Effective Date and shall terminate August 31, 2029, unless earlier terminated in accordance with the termination provisions below (the “Term”).”

2.With effect from the Amendment Effective Date, Clause 28 of the MESA shall be deleted in its entirety and be replaced by the following revised Clause:

“28. The following clauses contained in this Agreement, 14 (Limited Warranty); 15 (Confidentiality); 16 (Property Rights and Software Licenses); 17 (Patents); 18 (Limitations of Liability and Remedies); 33 (Escrow Agreement); Schedule 1; Schedule 2; Schedule 3; and any other clause or term that would, by its nature, be deemed or reasonably expected to survive termination of this Agreement, will survive the termination or expiration of this Agreement.”

3.Except as provided herein, all other terms, conditions and provisions of the MESA shall remain in full force and effect.

4.This agreement may be entered into electronically and in the form of two or more counterparts, each executed by one or more of the Parties but will not be effective until all Parties have executed and
Page 1 of 2



delivered at least one counterpart. Each counterpart will be an original of this agreement and all the counterparts taken together will constitute one instrument.

5.This agreement shall be governed by and construed in accordance with the laws of the State of New York and the United States, excluding its conflicts of law principles.


IN WITNESS OF WHICH, the Parties have caused this agreement to be executed by their duly authorized corporate officers or representatives as of the date first above written.

Insulet CorporationATS Corporation
By: /s/ James Flinn
By:/s/ Nick Anghel
Name: James Flinn
Name: Nick Anghel
Title: VP, Global Manufacturing Engineering
Title: General Manager – Life Sciences, Systems Cambridge
Date: 10-Jul-2024
Date: 11-Jul-2024

Page 2 of 2

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer